Inventiva (NASDAQ:IVA) Stock Price Up 6.7% – Here’s What Happened

Inventiva S.A. Sponsored ADR (NASDAQ:IVA)’s share price rose 6.7% during trading on Thursday . The stock traded as high as $6.59 and last traded at $6.5840. Approximately 238,937 shares changed hands during mid-day trading, a decline of 57% from the average daily volume of 553,148 shares. The stock had previously closed at $6.17.

Analyst Upgrades and Downgrades

A number of equities research analysts have weighed in on the company. Barclays initiated coverage on Inventiva in a research report on Tuesday, January 27th. They set an “overweight” rating and a $18.00 target price for the company. Leerink Partners initiated coverage on Inventiva in a research report on Monday, January 12th. They set an “outperform” rating and a $12.00 price target on the stock. Wolfe Research raised shares of Inventiva to a “strong-buy” rating in a research report on Thursday, November 6th. Guggenheim lowered their price target on Inventiva from $13.00 to $11.00 and set a “buy” rating for the company in a research report on Tuesday, November 18th. Finally, HC Wainwright set a $24.00 price objective on shares of Inventiva and gave the company a “buy” rating in a report on Wednesday, January 28th. Two research analysts have rated the stock with a Strong Buy rating, seven have given a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Buy” and an average price target of $16.22.

Inventiva Stock Performance

The firm’s 50-day moving average is $5.51 and its two-hundred day moving average is $5.07.

Hedge Funds Weigh In On Inventiva

Several hedge funds and other institutional investors have recently modified their holdings of the business. Paradigm Biocapital Advisors LP purchased a new stake in Inventiva during the 4th quarter valued at about $18,600,000. ADAR1 Capital Management LLC purchased a new stake in shares of Inventiva in the fourth quarter valued at approximately $12,601,000. Millennium Management LLC increased its holdings in shares of Inventiva by 2,267.7% in the fourth quarter. Millennium Management LLC now owns 2,652,570 shares of the company’s stock valued at $12,334,000 after purchasing an additional 2,540,540 shares during the last quarter. UBS Group AG lifted its position in Inventiva by 28,881.6% during the fourth quarter. UBS Group AG now owns 2,643,702 shares of the company’s stock worth $12,293,000 after buying an additional 2,634,580 shares in the last quarter. Finally, SymBiosis Capital Partners LLC acquired a new position in Inventiva during the fourth quarter worth $12,090,000. 19.06% of the stock is owned by hedge funds and other institutional investors.

About Inventiva

Inventiva (NASDAQ: IVA) is a clinical‐stage biopharmaceutical company focused on the discovery, development and commercialization of small molecule therapies for the treatment of metabolic, inflammatory, and fibrotic diseases. The company’s core expertise lies in the modulation of nuclear receptors and signaling pathways that regulate fibrosis, inflammation and metabolic dysfunction. Inventiva’s scientific platform integrates medicinal chemistry, in vitro and in vivo pharmacology, and translational sciences to advance a diversified pipeline of therapeutic candidates.

The company’s lead asset, lanifibranor (IVA337), is a pan-PPAR agonist in Phase III development for nonalcoholic steatohepatitis (NASH) and has demonstrated anti-inflammatory and anti-fibrotic effects in preclinical and clinical studies.